Journal Articles


Murray,J.R., Kopka,K., Afshar-Oromieh,A.: Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership. Radiotherapy and Oncology 129 (2), 387-388, 2018.

Cerna,T., Hrabeta,J., Eckschlager,T., Frei,E., Schmeiser,H.H., Arlt,V.M., Stiborova,M.: The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells. International Journal of Molecular Sciences 19 (1), 2018.

Rathke,H., Giesel,F.L., Flechsig,P., Kopka,K., Mier,W., Hohenfellner,M., Haberkorn,U., Kratochwil,C.: Repeated (177)Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. Journal of Nuclear Medicine 59 (3), 459-465, 2018.

Abd Rahim,M.S., Sommer,L.A.M., Wacker,A., Schaad,M., Dames,S.A.: H-1, N-15, and C-13 chemical shift assignments of the micelle immersed FAT C-terminal (FATC) domains of the human protein kinases ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) fused to the B1 domain of streptococcal protein G (GB1). Biomolecular Nmr Assignments 12 (1), 149-154, 2018.

Reed,L., Mrizova,I., Barta,F., Indra,R., Moserova,M., Kopka,K., Schmeiser,H.H., Wolf,C.R., Henderson,C.J., Stiborova,M., Phillips,D.H., Arlt,V.M.: Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice. Archives of Toxicology 92 (4), 1625-1638, 2018.

Paddubny,K., Freitag,M.T., Kratochwil,C., Koerber,S., Radtke,J.P., Sakovich,R., Kopka,K., Giesel,F.L.: Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical Genitourinary Cancer 16 (2), 103-105, 2018.

Simoes,M.L., Hockley,S.L., Schwerdtle,T., GamboadaCosta,G., Schmeiser,H.H., Phillips,D.H., Arlt,V.M.: Correction: Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. (vol 232, pg 86, 2008). Toxicology and Applied Pharmacology 344, 75-75, 2018.

Giesel,F.L., Will,L., Paddubny,K., Kremer,C., Rathke,H., Radtke,J.P., Kopka,K., Haufe,S., Haberkorn,U., Kratochwil,C.: [18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clinical Genitourinary Cancer 16 (2), 111-113, 2018.

Stiborova,M., Dracinska,H., Borek-Dohalska,L., Klusonova,Z., Holecova,J., Martinkova,M., Schmeiser,H.H., Arlt,V.M.: Exposure to endocrine disruptors 17alpha-ethinylestradiol and estradiol influences cytochrome P450 1A1-mediated genotoxicity of benzo[a]pyrene and expression of this enzyme in rats. Toxicology 400-401, 48-56, 2018.

Makarem,A., Konrad,M., Liolios,C., Kopka,K.: A Convenient Synthesis for HBED-CC-tris(tert-butyl ester). Synlett 29 (9), 1239-1243, 2018.

Giesel,F.L., Will,L., Lawal,I., Lengana,T., Kratochwil,C., Vorster,M., Neels,O., Reyneke,F., Haberkorn,U., Kopka,K., Sathekge,M.: Intraindividual Comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. Journal of Nuclear Medicine 59 (7), 1076-1080, 2018.

Afshar-Oromieh,A., Debus,N., Uhrig,M., Hope,T.A., Evans,M.J., Holland-Letz,T., Giesel,F.L., Kopka,K., Hadaschik,B., Kratochwil,C., Haberkorn,U.: Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 45 (12), 2045-2054, 2018.

Wohak,L.E., Baranski,A.C., Krais,A.M., Schmeiser,H.H., Phillips,D.H., Arlt,V.M.: The impact of p53 function on the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone and its metabolites 3-aminobenzanthrone and N-hydroxy-3-aminobenzanthrone in human cells. Mutagenesis 33 (4), 311-321, 2018.

Hugenberg,V., Behrends,M., Wagner,S., Hermann,S., Schäfers,M., Kolb,H.C., Szardenings,K., Walsh,J.C., Gomez,L.F., Kopka,K., Haufe,G.: Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on ypsilon-fluorinated alpha-sulfonylaminohydroxamic acid. EJNMMI Radiopharmacy and Chemistry 3 (10), 2018.

Baranski,A.C., Schafer,M., Bauder-Wust,U., Roscher,M., Schmidt,J., Stenau,E., Simpfendorfer,T., Teber,D., Maier-Hein,L., Hadaschik,B., Haberkorn,U., Eder,M., Kopka,K.: PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. Journal of Nuclear Medicine 59 (4), 639-645, 2018.

Giesel,F.L., Will,L., Kesch,C., Freitag,M., Kremer,C., Merkle,J., Neels,O.C., Cardinale,J., Hadaschik,B., Hohenfellner,M., Kopka,K., Haberkorn,U., Kratochwil,C.: Biochemical Recurrence of Prostate Cancer: Initial Results with [(18)F]PSMA-1007 PET/CT. Journal of Nuclear Medicine 59 (4), 632-635, 2018.

Liolios,C., Buchmuller,B., Bauder-Wüst,.U, Schäfer,M., Leotta,K., Haberkorn,U., Eder,M., Kopka,K.: Monomeric and Dimeric (68)Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs). Journal of Medicinal Chemistry 61 (5), 2062-2074, 2018.

Sachpekidis,C., Baeumer,P., Kopka,K., Hadaschik,B.A., Hohenfellner,M., Kopp-Schneider,A., Haberkorn,U., Dimitrakopoulou-Strauss,A.: Ga-68-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 45 (6), 904-912, 2018.

Sachpekidis,C., Goldschmidt,H., Kopka,K., Kopp-Schneider,A., Dimitrakopoulou-Strauss,A.: Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined F-18-FDG and F-18-FLT PET/CT imaging. EJNMMI Research 8, 2018.

Afshar-Oromieh,A., Sattler,L.P., Steiger,K., Holland-Letz,T., da Cunha,M.L., Mier,W., Neels,O., Kopka,K., Weichert,W., Haberkorn,U.: Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 45 (7), 1179-1187, 2018.

Sachpekidis,C., Pan,L., Hadaschik,B.A., Kopka,K., Haberkorn,U., Dimitrakopoulou-Strauss,A.: (68)Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. American Journal of Nuclear Medicine and Molecular Imaging 8 (5), 351-359, 2018.

Freitag,M.T., Kesch,C., Cardinale,J., Flechsig,P., Floca,R., Eiber,M., Bonekamp,D., Radtke,J.P., Kratochwil,C., Kopka,K., Hohenfellner,M., Stenzinger,A., Schlemmer,H.P., Haberkorn,U., Giesel,F.: Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging 45 (3), 340-347, 2018.

Giesel,F.L., Knorr,K., Spohn,F., Will,L., Maurer,T., Flechsig,P., Neels,O., Schiller,K., Amaral,H., Weber,W., Schwaiger,M., Hohenfellner,M., Kratochwil,C., Debus,J., Haberkorn,U., Choyke,P., Kramer,V., Kopka,K., Eiber,M.: Detection efficacy of [(18)F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy. Journal of Nuclear Medicine 2018.


Gasch,C., Düwel,C., Kopka,K., Kratochwil,C., Vinsensia,M., Eiber,M., Maurer,T., Haberkorn,U., Hadaschik,B., Giesel,F.L.: Significance of PSMA imaging in prostate cancer. Urologe / A 56 (1), 3-12, 2017.

Stiborová,M., Indra,R., Moserová,M., Bořek-Dohalská,L., Hodek,P., Frei,E., Kopka,K., Schmeiser,H.H., Arlt,V.M.: Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems. Chemistry 148 (11), 1959-1969, 2017.

Giesel,F.L., Kesch,C., Yun,M., Cardinale,J., Haberkorn,U., Kopka,K., Kratochwil,C., Hadaschik,B.A.: 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clinical Genitourinary Cancer 15 (3), e497-e499, 2017.

Fendler,W.P., Eiber,M., Beheshti,M., Bomanji,J., Ceci,F., Cho,S., Giesel,F., Haberkorn,U., Hope,T.A., Kopka,K., Krause,B.J., Mottaghy,F.M., Schoeder,H., Sunderland,J., Wan,S., Wester,H.J., Fanti,S., Herrmann,K.: 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging 44 (6), 1014-1024, 2017.

Stiborová,M., Indra,R., Frei,E., Kopečková,K., Schmeiser,H.H., Eckschlager,T., Adam,V., Heger,Z., Arlt,V.M., Martínek,V.: Cytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine. Chemistry 2017.

Baranski,A.-C., Schäfer,M., Bauder-Wüst,U., Wacker,A., Schmidt,J., Liolios,C., Mier,W., Haberkorn,U., Eisenhut,M., Kopka K., Eder,M.: Improving the imaging contrast of 68Ga-PSMA-11 by targeted linker design: introduction of charged spacer motives and their impact on the pharmacokinetic properties. Bioconjugate Chemistry 2017.

Liolios,C., Buchmuller,B., Bauder-Wüst,U., Schäfer,M., Leotta,K., Haberkorn,U., Eder,M., Kopka,K.: 68Ga-labeled Bombesin analogues: monomeric and dimeric HBED-CC chelator conjugates for PET imaging of GRPr expressing tumors. Journal of Medicinal Chemistry 2017.

Baranski,A.C., Schäfer,M., Bauder-Wüst,U., Wacker,A., Schmidt,J., Liolios,C., Mier,W., Haberkorn,U., Eisenhut,M., Kopka,K., Eder,M.: Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjugate Chemistry 28 (9), 2485-2492, 2017.

Afshar-Oromieh,A., Holland-Letz,T., Giesel,F.L., Kratochwil,C., Mier,W., Haufe,S., Debus,N., Eder,M., Eisenhut,M., Schäfer,M., Neels,O., Hohenfellner,M., Kopka,K., Kauczor,H.U., Debus,J., Haberkorn,U.: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European Journal of Nuclear Medicine and Molecular Imaging 44 (8), 1258-1268, 2017.

Will,L., Sonni,I., Kopka,K., Kratochwil,C., Giesel,F.L., Haberkorn,U.: Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging 61 (2), 168-180, 2017.

Breyholz,H.J., Kopka,K., Schäfers,M., Wagner,S.: Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases. Pharmaceuticals 10 (2), 2017.

Vinsensia,M., Choyke,P.L., Hadaschik,B., Holland-Letz,T., Moltz,J., Kopka,K., Rauscher,I., Mier,W., Schwaiger,M., Haberkorn,U., Maurer,T., Kratochwil,C., Eiber,M., Giesel,F.: 68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. Journal of Nuclear Medicine 2017.

Rathke,H., Giesel,F.L., Flechsig,P., Kopka,K., Mier,W., Hohenfellner,M., Haberkorn,U., Kratochwil,C.: Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq. Journal of Nuclear Medicine 2017.

Kesch,C., Vinsensia,M., Radtke,J.P., Schlemmer,H.P., Heller,M., Ellert,E., Holland-Letz,T., Duensing,S., Grabe,N., Afshar-Oromieh,A., Wieczorek,K., Schäfer,M., Neels,O.C., Cardinale,J., Kratochwil,C., Hohenfellner,M., Kopka,K., Haberkorn,U., Hadaschik,B.A., Giesel,F.L.: Intra-individual comparison of 18F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. Journal of Nuclear Medicine 2017.

Stiborova,M., Moserova,M., Mrizova,I., Dracinska,H., Martinek,V., Indra,R., Frei,E., Adam,V., Kizek,R., Schmeiser,H.H., Kubackova,K., Arlt,V.M.: CORRECTION: Induced expression of microsomal cytochrome b(5) determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I) (vol 147, pg 897, 2016). Monatshefte fuer Chemie 148 (10), 1897-1897, 2017.

Kopka K, Benesova M, Barinka C, Haberkorn U, Babich J: Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine 58 (Suppl 2), 17S-26S, 2017.

Haberkorn U, Mier W, Kopka K, Herold-Mende C, Altmann A, Babich J: Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine 58 (Suppl 2), 27S-33S, 2017.

Heusser,T., Mann,P., Rank,C.M., Schaefer,M., Dimitrakopoulou-Strauss,A., Schlemmer,H.P., Hadaschik,B.A., Kopka,K., Bachert,P., Kachelriess,M., Freitag,M.T.: Investigation of the halo-artifact in Ga-68-PSMA-11-PET/MRI. PLoS ONE 12 (8), e0183329, 2017.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, Debus N, Eder M, Eisenhut M, Schaefer M, Neels O, Hohenfellner M, Kopka K, Kauczor HU, Debus J, Haberkorn U: CORRECTION: Diagnostic performance of Ga-68-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients (vol 44, pg 1258, 2017). European Journal of Nuclear Medicine and Molecular Imaging 44 (10), 1781-1781, 2017.

Afshar-Oromieh A, Wolf M, Haberkorn U, Kachelriess M, Gnirs R, Kopka K, Schlemmer HP, Freitag MT: Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging 44 (10), 1636-1646, 2017.

Haberkorn,U., Giesel,F., Kopka,K., Kratochwil,C.: Radiotherapy with PSMA ligands in prostate cancer. Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique 41 (3), 232-234, 2017.

Kesch,C., Kratochwil,C., Mier,W., Kopka,K., Giesel,F.L.: Ga-68 or F-18 for Prostate Cancer Imaging. Journal of Nuclear Medicine 58 (5), 687-688, 2017.

Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, Kopka K, Haberkorn U: The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine 58 (5), 750-755, 2017.

Arlt,V.M., Meinl,W., Florian,S., Nagy,E., Barta,F., Thomann,M., Mrizova,I., Krais,A.M., Liu,M., Richards,M., Mirza,A., Kopka,K., Phillips,D.H., Glatt,H., Stiborova,M., Schmeiser,H.H.: Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. Archives of Toxicology 91 (4), 1957-1975, 2017.

Freitag, M.F., Radtke, J.P., Afshar-Oromieh, A., Roethke, M.C., Hadaschik, B.A., Gleave, M., Bonekamp, D., Kopka, K., Eder, M., Heusser, T., Kachelriess, M., Wieczorek, K., Sachpekidis, C., Flechsig, P., Giesel, F., Hohenfellner, M., Haberkorn, U., Schlemmer, H.P., Dimitrakopoulou-Strauss, A.: Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging 44 (5), 776-787, 2017.

Giesel,F.L., Hadaschik,B., Cardinale,J., Radtke,J., Vinsensia,M., Lehnert,W., Kesch,C., Tolstov,Y., Singer,S., Grabe,N., Duensing,S., Schäfer,M., Neels,O.C., Mier,W., Haberkorn,U., Kopka,K., Kratochwil,C.: F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 44 (4), 678-688, 2017.

Cardinale,J., Schäfer,M., Benešová,M., Bauder-Wüst,U., Leotta,K., Eder,M., Neels,O.C., Haberkorn,U., Giesel,F.L., Kopka,K.: Preclinical Evaluation of F-18-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. Journal of Nuclear Medicine 58 (3), 425-431, 2017.

Hugenberg V, Wagner S, Kopka K, Schaefers M, Schuit RC, Windhorst AD, Hermann S: Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation. Journal of Medicinal Chemistry 60 (1), 307-321, 2017.

Sachpekidis,C., Hillengass,J., Goldschmidt,H., Wagner,B., Haberkorn, U., Kopka,K., Dimitrakopoulou-Strauss,A.: Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging 44 (1), 50-62, 2017.


Haberkorn,U., Eder,M., Kopka,K., Babich,J.W., Eisenhut,M.: New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin Cancer Res. 22(1), 9-15, 2016.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A: 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine 57 (12), 1941-1944, 2016.

Gerwien,H., Hermann,S., Zhang,X., Korpos,E., Song,J., Kopka,K., Faust,A., Wenning,C., Gross,C.C., Honold,L., Melzer,N., Opdenakker,G., Wiendl,H., Schäfers,M., Sorokin,L.: Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Science Translational Medicine 8 (364), 2016.

Stiborova M, Arlt VM, Schmeiser HH: Balkan endemic nephropathy: an update on its aetiology. Archives of Toxicology 90 (11), 2595-2615, 2016.

Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A: 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. Clinical Nuclear Medicine 41 (11), e473-e479, 2016.

Labib,S., Williams,A., Guo,C.H., Leingartner,K., Arlt,V.M., Schmeiser,H.H., Yauk,C.L., White,P.A., Halappanavar,S.: Comparative transcriptomic analyses to scrutinize the assumption that genotoxic PAHs exert effects via a common mode of action. Archives of Toxicology 90 (10), 2461-2480, 2016.

Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U: PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Journal of Nuclear Medicine 57 (8), 1170-1176, 2016.

Sulc,M., Indra,R., Moserova,M., Schmeiser,H.H., Frei,E., Arlt,V.M., Stiborova,M.: The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers. Environmental and Molecular Mutagenesis 57 (3), 229-235, 2016.

Milichovsky,J., Barta,F., Schmeiser,H.H., Arlt,V.M., Frei,E., Stiborova,M., Martinek,V.: Active Site Mutations as a Suitable Tool Contributing to Explain a Mechanism of Aristolochic Acid I Nitroreduction by Cytochromes P450 1A1, 1A2 and 1B1. International Journal of Molecular Sciences 17 (2), 2016.

Benesova,M., Bauder-Wuest,U., Schaefer,M., Klika,K.D., Mier,W., Haberkorn,U., Kopka,K., Eder,M.: Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. Journal of Medicinal Chemistry 59 (5), 1761-1775, 2016.

Liolios,C.C., Xanthopoulos,S., Loudos,G., Varvarigou,A.D., Sivolapenko,GB.: Co-administration of succinylated gelatine with a (99m)Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake. Nuclear Medicine and Biology 43 (10), 625-634, 2016.

Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL: Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.. Seminars in Nuclear Medicine 46 (5), 405-418, 2016.

Stiborova M, Indra R, Moserova M, Frei E, Schmeiser HH, Kopka K, Philips DH, Arlt VM: NADH:Cytochrome b5 Reductase and Cytochrome b5 Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene. Chemical Research in Toxicology 29 (8), 1325-1334, 2016.

Stiborova M, Indra R, Moserova M, Sulc M, Hodek P, Frei E, Schmeiser HH, Arlt VM: NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[a]pyrene catalyzed with rat hepatic microsomes and cytochrome P450 1A1. Monatshefte fuer Chemie 147 (5), 847-855, 2016.

Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A: (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43 (7), 1288-1299, 2016.

Liolios C, Schaefer M, Haberkorn U, Eder M, Kopka K: Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. Bioconjugate Chemistry 27 (3), 737-751, 2016.

Ó Halloran PJ, Viel T, Murray DW, Wachsmuth L, Schwegmann K, Wagner S, Kopka K, Jarzabek MA, Dicker P, Hermann S, Faber C, Klasen T, Schaefers M, Ó Brien D, Prehn JH, Jacobs AH, Byrne AT: Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. European Journal of Nuclear Medicine and Molecular Imaging 43 (9), 1673-1683, 2016.

Afshar-Oromieh A, Hetzheim H, Kuebler W, Kratochwil C, Giesel FL, Hope TA, Eder M, Eisenhut M, Kopka K, Haberkorn U: Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging 43 (9), 1611-1620, 2016.

Dracinska H, Barta F, Levova K, Hudecova A, Moserova M, Schmeiser HH, Kopka K, Frei E, Arlt VM, Stiborova M: Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo. Toxicology 344-346, 7-18, 2016.

Hugenberg V, Hermann S, Galla F, Schaefers M, Wunsch B, Kolb HC, Szardenings K, Lebedev A, Walsh JC, Mocharla VP, Gangadharmath UB, Kopka K, Wagner S: Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability. Nuclear Medicine and Biology 43 (7), 424-437, 2016.

Giesel,F.L., Sterzing,F., Schlemmer,H.P., Holland-Letz,T., Mier,W., Rius,M., Afshar-Oromieh,A., Kopka,K., Debus,J., Haberkorn,U., Kratochwil,C.: Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 43 (8), 1400-1406, 2016.

Wild E, Teber D, Schmid D, Simpfendorfer T, Mueller M, Baranski AC, Kenngott H, Kopka K, Maier-Hein L: Robust augmented reality guidance with fluorescent markers in laparoscopic surgery. International Journal of Computer Assisted Radiology and Surgery 11 (6), 899-907, 2016.

Ioannidis H, Drakopoulos A, Tzitzoglaki C, Homeyer N, Kolarov F, Gkeka P, Freudenberger K, Liolios C, Gauglitz G, Cournia Z, Gohlke H, Kolocouris A: Alchemical Free Energy Calculations and Isothermal Titration Calorimetry Measurements of Aminoadamantanes Bound to the Closed State of Influenza A/M2TM. Journal of Chemical Information and Modeling 56 (5), 862-876, 2016.

Radchenko V, Bouziotis P, Tsotakos T, Paravatou-Petsotas M, la Fuente Ad, Loudos G, Harris AL, Xanthopoulos S, Filosofov D, Hauser H, Eisenhut M, Ponsard B, Roesch F: Labeling and preliminary in vivo assessment of niobium-labeled radioactive species: A proof-of-concept study. Nuclear Medicine and Biology 43 (5), 280-287, 2016.

Stiborova M, Moserova M, Mrizova I, Dracinska H, Martinek V, Indra R, Frei E, Adam V, Kizek R, Schmeiser HH, Kubackova K, Arlt VM: Induced expression of microsomal cytochrome determined at mRNA and protein levels in rats exposed to ellipticine, benzo[]pyrene, and 1-phenylazo-2-naphthol (Sudan I). Monatshefte fuer Chemie 147 (5), 897-904, 2016.

Kanaan,N., Hassoun,Z., Raggi,C., Jadoul,M., Mourad,M., De Meyer,M., Aydin,S., Schmeiser,H.H., Cosyns,J.P., Goffin,E.: Long term outcome of kidney recipients transplanted for aristolochic acid nephropathy. Transplantation 100 (2), 416-421, 2016.

Kucab JE, Zwart EP, van Steeg H, Luijten M, Schmeiser HH, Phillips DH, Arlt VM: TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts. DNA Repair 39, 21-33, 2016.

Krais,A.M., Speksnijder,E.N., Melis,J.P., Indra,R., Moserova,M., Godschalk, R.W., van Schooten,F.J., Seidel,A., Kopka,K., Schmeiser,H.H., Stiborova,M., Phillips,D.H., Luijten,M., Arlt,V.M.: The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice. Archives of Toxicology 90 (4), 839-851, 2016.

Haberkorn,U., Kopka,K., Hadaschik,B.: Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer. European Urology 69 (3), 397-399, 2016.

Freitag,M.T., Radtke,J.P., Hadaschik,B.A., Kopp-Schneider,A., Eder,M., Kopka,K., Haberkorn,U., Roethke,M., Schlemmer,H.P., Afshar-Oromieh,A.: Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43(1), 70-83, 2016.

Sterzing,F., Kratochwil,C., Fiedler,H., Katayama,S., Habl,G., Kopka,K., Afshar-Oromieh,A., Debus,J., Haberkorn,U., Giesel,F.L.: (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging 43(1), 34-41, 2016.

Delker,A., Fendler,W.P., Kratochwil,C., Brunegraf,A., Gosewisch,A., Gildehaus,F.J., Tritschler,S., Stief,C.G., Kopka,K., Haberkorn,U., Bartenstein,P., Böning,G: Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43(1), 42-51, 2016.


Waldmann,C.M., Hermann,S., Faust,A., Riemann,B., Schober,O., Schäfers,M., Haufe,G., Kopka,K.: Novel fluorine-18 labeled 5-(1-pyrrolidinylsulfonyl)-7-azaisatin derivatives as potential PET tracers for in vivo imaging of activated caspases in apoptosis.. Bioorganic and Medicinal Chemistry 23 (17), 5734-5739, 2015.

Neels,O.C., Remde,Y., Hennrich,U., Kopka,K.: An adapted GMP-compliant production of [18F]FAZA on a cassette based synthesis unit for the detection of hypoxia using positron emission tomography (PET). European Journal of Nuclear Medicine and Molecular Imaging 42 (1), 483, 2015.

Krais,A.M., Muehlbauer,K.R., Kucab,J.E., Chinbuah,H., Cornelius,M.G., Wei,Q.X., Hollstein,M., Phillips,D.H., Arlt,V.M., Schmeiser,H.H.: Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts. Toxicology in vitro 29 (1), 34-43, 2015.

Benesova,M., Schaefer,M., Bauder-Wuest,U., Afshar-Oromieh,A., Kratochwil,C., Mier,W., Haberkorn,U., Kopka,K., Eder,M.: Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine 56 (6), 914-920, 2015.

Afshar-Oromieh,A., Hetzheim,H., Kratochwil,C., Benesova,M., Eder,M., Neels,O.C., Eisenhut,M., Kuebler,W., Holland-Letz,T., Giesel,F.L., Mier,W., Kopka,K., Haberkorn,U.: The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Journal of Nuclear Medicine 56 (11), 1697-1705, 2015.

Afshar-Oromieh,A., Avtzi,E., Giesel,F.L., Holland-Letz,T., Linhart,H.G., Eder,M., Eisenhut,M., Boxler,S., Hadaschik,B.A., Kratochwil,C., Weichert,W., Kopka,K., Debus,J., Haberkorn,U.: The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 42 (2), 197-209, 2015.

Afshar-Oromieh,A., Kratochwil,C., Eder,M., Eisenhut,M., Kopka,K., Haberkorn,U.: Diagnosis of Recurrent Prostate Cancer with PSMA-Ligand PET/CT and Clinical Introduction of PSMA-based Radioligand Therapy   (Rezidivdiagnostik des Prostatakarzinoms mit PSMA-Liganden PET/CT und die Initialen klinischen Erfahrungen mit der PSMA-basierten Radioligandentherapie). Nuklearmediziner 38, 124-130, 2015.

Baumgart,T., Kriesen,S., Neels,O., Hildebrandt,G., Manda,K.: Investigation of epothilone B-induced cell death mechanisms in human epithelial cancer cells -in consideration of combined treatment with ionizing radiation.. Cancer Investigation 33 (6), 213-224, 2015.

Behrends,M., Wagner,S., Kopka,K., Schober,O., Schäfers,M., Kumbhar,S., Waller,M., Haufe,G.: New matrix metalloproteinase inhibitors based on y-fluorinated a-aminocarboxylic and a-aminohydroxamic acids. Bioorganic and Medicinal Chemistry 23 (13), 3809-3818, 2015.

Giesel,F.L., Fiedler,H., Stefanova,M., Sterzing,F., Rius,M., Kopka,K., Moltz,J.H., Afshar-Oromieh,A., Choyke,P.L., Haberkorn,U., Kratochwil,C.: PSMA PET/CT with Glu-urea-Lys-(Ahx)-[(68)Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 42 (12), 1794-1800, 2015.

Junker,A., Kokornaczyk,A.K., Zweemer,A.J., Frehland,B., Schepmann,D., Yamaguchi,J., Itami,K., Faust,A., Hermann,S., Wagner,S., Schaefer,M., Koch,M., Weiss,C., Heitman,L.H., Kopka,K., Wunsch,B.: Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. Organic and Biomolecular Chemistry 13 (8), 2407-2422, 2015.

Kratochwil,C., Giesel,F.L., Leotta,K., Eder,M., Hoppe-Tich,T., Youssoufian,H., Kopka,K., Babich,J.W., Haberkorn,U.: PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. Journal of Nuclear Medicine 56 (2), 293-298, 2015.

Kucab,J.E., van Steeg,H., Luijten,M., Schmeiser,H.H., White,P.A., Phillips,D.H., Arlt,V.M.: TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts. Mutation Research 773, 48-62, 2015.

Roumeguere,T., Broeders,N., Jayswal,A., Rorive,S., Quakels,T., Lemy,A., Podzik,A., Arlt,V.M., Schmeiser,H.H., Nortier,J.L.: Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transplant International 28 (2), 199-205, 2015.

Stiborová,M., Bárta,F., Levová,K., Hodek,P., Schmeiser,H.H., Arlt,V.M., Martínek,V.: A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and their Contributions to this Reaction in Human and Rat Livers: Experimental and Theoretical Approaches. International Journal of Molecular Sciences 16 (11), 27561-27575, 2015.

Zinnhardt,B., Viel,T., Wachsmuth,L., Vrachimis,A., Wagner,S., Breyholz,H.J., Faust,A., Hermann,S., Kopka,K., Faber,C., Dollé,F., Pappata,S., Planas,A.M., Tavitian,B., Schäfers,M., Sorokin,L.M., Kuhlmann,M.T., Jacobs, A.H.: Multimodal imaging reveals temporal and spatial microglia and matrix metalloproteinase activity after experimental stroke. Journal of Cerebral Blood Flow and Metabolism 35 (11), 1711-1721, 2015.


Eder,M.*, Neels,O.*, Birner,M., Bauder-Wüst,U., Remde,Y., Schäfer,M., Hennrich,U., Eisenhut,M., Afshar-Oromieh,A., Haberkorn,U., Kopka,K. Novel preclinical and radiopharmaceutical aspects of Ga-68-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals  7, 779-796, 2014. *both authors contributed equally

Afshar-Oromieh,A., Zechmann,C.M., Malcher,A., Eder,M., Eisenhut,M., Linhart,H.G., Holland-Letz,T., Hadaschik,B.A., Giesel,F.L., Debus,J., Haberkorn,U.: Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1), 11-20, 2014.

Eder, M., Schäfer, M., Bauder-Wüst, U., Haberkorn, U., Eisenhut, M., Kopka, K.: Preclinical Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74(6), 659-668, 2014.

Junker,A., Schepmann,D., Yamaguchi,J., Itami,K., Faust,A., Kopka,K., Wagner,S., Wünsch,B.: Diverse Modification of the 4-Methylphenyl Moiety of TAK-779 by Late-Stage Suzuki-Miyaura Cross-Coupling. Org Biomol Chem 12(1), 177-186, 2014.

Sachpekidis,C., Goldschmidt,H., Hose,D., Pan,L., Cheng,C., Kopka,K., Haberkorn,U., Dimitrakopoulou-Strauss,A.: PET/CT studies of multiple myeloma using F-18-FDG and F-18-NaF: comparison of distribution patterns and tracers’ pharmacokinetics. Eur J Nucl Med Mol Imaging 41(7), 1343-1353, 2014.

Schelhaas,S., Wachsmuth,L., Viel,T., Honess,D.J., Heinzmann,K., Smith,D.M., Hermann,S., Wagner,S., Kuhlmann,M.T., Müller-Tidow,C., Kopka,K., Schober,O., Schäfers,M., Schneider,R., Aboagye,E.O., Griffiths,J., Faber,C., Jacobs,A.H.: Variability of proliferation and diffusion in different lung cancer models as measured by F-18-FLT-PET and DW-MRI. J Nucl Med 55(6), 983-988, 2014.

Zechmann,C.M., Afshar-Oromieh,A., Armor,T., Stubbs,J.B., Mier,W., Hadaschik,B., Joyal,J., Kopka, ., Debus,J., Babich,J.W., Haberkorn,U.: Radiation dosimetry and first therapy results with a 124I/131I labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging, 41 (7), 1280-1292, 2014.


Afshar-Oromieh, A., Haberkorn, U., Eder, M., Eisenhut, M., Zechmann, C.M.: Ga-68-Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with F-18-FECH. Eur J Nucl Med Mol Imaging 39(6), 1085-1086, 2012.

Afshar-Oromieh, A., Haberkorn, U., Hadaschik, B., Habl, G., Eder, M., Eisenhut, M., Schlemmer, H.P., Roethke, M.C.: PET/MRI with a Ga-68-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 40(10), 1629-1630, 2013.

Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H.G., Hadaschik, B.A., Holland-Letz, T., Giesel, F.L., Kratochwil, C., Haufe, S., Haberkorn, U., Zechmann, C.M.: Reply to Reske et al.: PET imaging with a Ga-68-Gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(6), 971-972, 2013.

Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H.G., Hadaschik, B.A., Holland-Letz, T., Giesel, F.L., Kratochwil, C., Haufe, S., Haberkorn, U., Zechmann, C.M.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(4), 486-495, 2013. Erratum in: Eur J Nucl Med Mol Imaging 40(5), 797-798, 2013.

Eder, M., Eisenhut, M., Babich, J., Haberkorn, U.: PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 40(6), 819-23, 2013.

Eder, M., Löhr, T., Bauder-Wüst, U., Reber, M., Mier, W., Schäfer, M., Haberkorn, U., Eisenhut, M.: Pharmacokinetic Properties of Peptidic Radiopharmaceuticals: Reduced Uptake of (EH)3-Conjugates in Important Organs. J Nucl Med 54(8), 1327-1330, 2013.

Giesel, F., Stefanova, M., Schwartz, L.H., Afshar-Oromieh, A., Eisenhut, M., Haberkorn, U., Kratochwil C.: Impact of peptide receptor radionuclide therapy on the Ga-68-DOTATOC-PET/CT uptake in normal tissue. Q J Nucl Med Mol Imaging 57(2), 171-176, 2013.

Hugenberg, V., Riemann, B., Hermann, S., Schober, O., Schäfers, M., Szardenings, A.K., Lebedev, A., Gangadharmath, U., Kolb, H., Walsh, J., Zhang, W., Kopka, K., Wagner, S.: Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (Radio)synthesis, in vitro and first in vivo evaluation. J Med Chem 56(17), 6858-6870, 2013.

Limpachayaporn, P., Wagner, S., Kopka, K., Hermann, S., Schäfers, M., Haufe, G.: Synthesis, F-18-Radiolabeling and In Vivo Biodistribution Studies of N-Fluorohydroxybutyl Isatin Sulfonamides using Positron Emission Tomography. J Med Chem 56(11), 4509-4520, 2013.

Limpachayaporn, P., Riemann, B., Kopka, K., Schober, O., Schäfers, M., Haufe, G.: Influence of 4- or 5-substituents on the pyrrolidine ring of 5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin derivatives on their inhibitory activities towards caspases-3 and -7. Eur J Med Chem 64, 562-578, 2013.

Limpachayaporn, P., Schäfers, M., Schober, O., Kopka, K., Haufe, G.: Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: Nonradioactive counterparts of putative PET-compatible apoptosis imaging agents. Bioorg Med Chem 21(7), 2025-2036, 2013.

Maschauer, S., Michel, K., Tripal, P., Büther, K., Kuwert, T., Schober, O., Kopka, K., Riemann, B., Prante, O.: Synthesis and In vivo Evaluation of an 18F-Labeled Glycoconjugate of PD156707 for Imaging ETA Receptor Expression in Thyroid Carcinoma by Positron Emission Tomography. Am J Nucl Med Mol Imaging 3(5), 425-436, 2013.

Mier, W., Krämer, S., Zitzmann, S., Altmann, A., Leotta, K., Schierbaum, U., Schnölzer, M., Eisenhut, M., Haberkorn, U.: PEGylation enables the specific tumor accumulation of a peptide identified by phage display. Org Biomol Chem 11(16), 2706-2711, 2013.

Viel, T., Schelhaas, S., Wagner, S., Wachsmuth, L., Schwegmann, K., Kuhlmann, M., Faber, C., Kopka, K., Schäfers, M., Jacobs, A.H.: Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using F-18-FLT-PET imaging. PLoS One 8(7), e67911, 2013.

Waldmann, C., Schober, O., Haufe, G., Kopka, K.: A Closer Look at the Bromine Lithium Exchange with tert Butyllithium in an Aryl Sulfonamide Synthesis. Org Lett 15(12), 2954-2957, 2013.


Afshar-Oromieh, A., Haberkorn, U., Eder, M., Eisenhut, M., Zechmann, C.M.: Ga-68-Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with F-18-FECH. Eur J Nucl Med Mol Imaging 39(6), 1085-1086, 2012.

Afshar-Oromieh, A., Giesel, F.L., Linhart, H.G., Haberkorn, U., Haufe, S., Combs, S.E., Podlesek, D., Eisenhut, M., Kratochwil, C.: Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 39(9), 1409-1415, 2012.

Altmann, A., Markert, A., Askoxylakis, V., Schöning, T., Jesenofsky, R., Eisenhut, M., Haberkorn, U.: Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. J Nucl Med 53(11), 1764-1771, 2012.

Braun, K., Beining, M., Wiessler, M., Lammers, T., Pipkorn, R., Hennrich, U., Nokihara, K., Semmler, W., Debus, J., Waldeck, W.: BioShuttle mobility in living cells studied with high-resolution FCS & CLSM methodologies. Int J Med Sci 9(5), 339-352, 2012.

Claesener, M., Breyholz, H.J., Hermann, S., Faust, A., Wagner, S., Schober, O., Schäfers, M., Kopka, K.: Efficient synthesis of a fluorine-18 labeled biotin derivative. Nucl Med Biol 39(8), 1189-1194, 2012.

Claesener, M., Schober, O., Wagner, S., Kopka, K.: Radiosynthesis of a 68Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging. Appl Radiat Isot 70(8), 1723-1728, 2012.

Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W.E., Wängler, C., Mier, W., Haberkorn, U., Eisenhut, M.: 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjugate Chem 23(4), 688-697, 2012.

Denoyer, D., Kirby, L., Waldeck, K., Roselt, P., Neels, O.C., Bourdier, T., Shepherd, R., Katsifis, A., Hicks, R.J. Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer. Eur J Nucl Med Mol Imaging 39(4), 703-712, 2012.

Hofman, M.S., Kong, G., Neels, O.C., Eu, P., Hong, E., Hicks, RJ.: High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 56(1), 40-47, 2012.

Hugenberg, V., Breyholz, H.J., Riemann, B., Hermann, S., Schober, O., Schäfers, M., Gangadharmath, U., Mocharla, V., Kolb, H., Walsh, J., Zhang, W., Kopka, K.*, Wagner, S*.: A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (Radio)synthesis, in vitro and first in vivo evaluation. J Med Chem 55(10), 4714-4727, 2012. *contributed equally

Hennrich, U., Seyler, L., Schäfer, M., Bauder-Wüst, U., Eisenhut, M., Semmler, W., Bäuerle, T.: Synthesis and in vitro evaluation of Ga-68-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. Bioorg Med Chem 20(4), 1502-1510, 2012.

Pipkorn, R., Wiessler, M., Waldeck, W., Hennrich, U., Nokihara, K., Beining, M., Braun, K.: Improved synthesis strategy for peptide nucleic acids (PNA) appropriate for cell-specific fluorescence imaging. Int J Med Sci 9(1), 1-10, 2012.

Radchenko, V., Hauser, H., Eisenhut, M., Vugts, D.J., van Dongen, G.A.M.S., Roesch, F.: Nb-90 - a potential PET nuclide: production and labeling of monoclonal antibodies. Radiochim Acta 100, 857-863, 2012.

Schäfer, M., Bauder-Wüst, U., Leotta, K., Zoller, F., Mier, W., Haberkorn, U., Eisenhut, M., Eder, M.: A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging

Schrigten, D., Breyholz, H.J., Wagner, S., Hermann, S., Schober, O., Schäfers, M., Haufe, G., Kopka, K.: A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-targeted Radiotracers for Positron Emission Tomography. J Med Chem 55(1), 223-232, 2012.


Aide, N., Kinross, K., Beauregard, J.M., Neels, O., Potdevin, T., Roselt, P., Dorow, D., Cullinane, C., Hicks, RJ.: A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors. Mol Imaging Biol 13, 518-525, 2011.

Baumann, A., Faust, A., Law, M.P., Kuhlmann, M.T., Kopka, K., Schäfers, M., Karst, U.: Metabolite Identification of a Radiotracer by Electrochemistry Coupled to Liquid Chromatography with Mass Spectrometric and Radioactivity Detection. Anal Chem 83(13), 5415-5421, 2011.

Cheng, C., Pan, L., Dimitrakopoulou-Strauss, A., Schäfer, M., Wängler, C., Wängler, B., Haberkorn, U., Strauss, L.G.: Comparison between Ga-68-bombesin (Ga-68-BZH3) and the cRGD tetramer Ga-68-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line. EJNMMI Res 1, 34, 2011.

Denoyer, D., Potdevin, T., Roselt, P., Neels, O.C., Kirby, L., Greguric, I., Katsifis, A., Dorow, D.S., Hicks, R.J.: Improved detection of regional melanoma metastasis using F-18-6-fluoro-N-[2-(diethylamino)ethyl]pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med 52(1), 115-122, 2011.

Dimitrakopoulou-Strauss, A., Seiz, M., Tuettenberg, J., Schmieder, K., Eisenhut, M., Haberkorn, U., Strauss, L.G. Pharmacokinetic studies of 68Ga-labeled Bombesin (Ga-68-BZH3) and F-18-FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med 36(2), 101-108, 2011.

Hofman, M.S., Beauregard, J.M., Barber, T.W., Neels, O.C., Eu, P., Hicks, R.J.: Ga-68 PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy. J Nucl Med 52(10), 1513-1519, 2011.

Ma, M.T., Neels, O.C., Denoyer, D., Roselt, P., Karas, J.A., Scanlon, D.B., White, J.M., Hicks, R.J., Donnelly, P.S.: Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging. Bioconjugate Chem 22(10), 2093-2103, 2011.

Michel, K., Büther, K., Law, M.P., Wagner, S., Schober, O., Hermann, S., Schäfers, M., Riemann, B., Höltke, C.*, Kopka, K.*: Development and Evaluation of Endothelin-A Receptor (Radio)-Ligands for Positron Emission Tomography. J Med Chem 54(4), 939-948, 2011. *contributed equally

Mühlhausen, U., Komljenovic, D., Bretschi, M., Leotta, K., Eisenhut, M., Semmler, W., Bäuerle, T.: A novel PET tracer for the imaging of αvβ3 and αvβ5 integrins in experimental breast cancer bone metastases. Contrast Media Mol Imaging 6(6), 413-420, 2011.

Oltmanns, D., Zitzmann-Kolbe, S., Mueller, A., Bauder-Wuest, U., Schäfer, M., Eder, M., Haberkorn, U., Eisenhut, M.: Zn(II)-bis(cyclen) complexes and the imaging of apoptosis/necrosis. Bioconjugate Chem 22(12), 2611-2624, 2011.

Pipkorn, R., Wießler, M., Waldeck, W., Lorenz, P., Mühlhausen, U., Fleischhacker, H., Koch, M., Braun, K.: Enhancement of the Click Chemistry for the inverse Diels Alder technology by functionalization of amide-based monomers. Int J Med Sci 8(5), 387-396, 2011.

Wängler, C., Schäfer, M., Schirrmacher, R., Bartenstein, P., Wängler, B.: DOTA derivatives for site-specific biomolecule-modification via click chemistry: synthesis and comparison of reaction characteristics. Bioorg Med Chem 19(12), 3864-3874, 2011.

Wagner, S.*, Faust, A.*, Breyholz, H.J., Schober, O., Schäfers, M., Kopka, K.: The MMP inhibitor (R)-2-(N-Benzyl-4-(2-F-18 fluoroethoxy)phenylsulphon-amido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. Appl Radiat Isot 69(6), 862-868, 2011. *contributed equally

Wießler, M., Hennrich, U., Pipkorn, R., Waldeck, W., Cao, L., Peter, J., Ehemann, V., Semmler, W., Lammers, T., Braun K.: Theranostic cRGD-BioShuttle Constructs Containing Temozolomide- and Cy7 For NIR-Imaging and Therapy. Theranostics 1, 381-394, 2011.


Aide, N., Desmonts, C., Beauregard, J.M., Beyer, T., Kinross, K., Roselt, P., Neels, O., Agostini, D., Bardet, S., Bouvard, G., Hicks, R.J.: High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. Eur J Nucl Med Mol Imaging 37(5), 991-1001, 2010.

Aide, N., Kinross, K., Cullinane, C., Roselt, P., Waldeck, K., Neels, O., Dorow, D., McArthur, G., Hicks, R.J.: F-18-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med 51(10), 1559-1564, 2010.

Altmann, A., Eisenhut, M., Bauder-Wüst, U., Markert, A., Askoxylakis, V., Hess-Stumpp, H., Haberkorn, U. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 37(12), 2286-2297, 2010.

Boy, R.G., Mier, W., Nothelfer, E.M., Altmann, A., Eisenhut, M., Kolmar, H., Tomaszowski, M., Krämer, S., Haberkorn, U.: Sunflower Trypsin Inhibitor 1 Derivatives as Molecular Scaffolds for the Development of Novel Peptidic Radiopharmaceuticals. Mol Imaging Biol 12(4), 377-385, 2010.

Breyholz, H.J., Wagner, S., Faust, A., Riemann, B., Höltke, C., Hermann, S., Schober, O., Schäfers, M., Kopka, K.: Radiofluorinated Pyrimidine-2,4,6-triones as Molecular Probes for Non-Invasive MMP-targeted Imaging. ChemMedChem 5(5), 777-789, 2010.

Eder, M., Knackmuss, S., Le Gall, F., Reusch, U., Rybin, V., Little, M., Haberkorn, U., Mier, W., Eisenhut, M.: Ga-68-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 37(7), 1397-1407, 2010.

Eder, M., Krivoshein, A.V., Backer, M., Backer, J.M., Haberkorn, U., Eisenhut, M.: ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for Ga-68 PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol 37(4), 405-412, 2010.

Denoyer, D., Greguric, I., Roselt, P., Neels, O.C., Aide, N., Taylor, S.R., Katsifis, A., Dorow, D.S., Hicks, RJ.: High-contrast PET of melanoma using F-18-MEL050, a selective probe for melanin with predominantly renal clearance. J Nucl Med 51(3), 441-447, 2010.

Hugenberg, V., Wagner, S., Kopka, K., Schober, O., Schäfers, M., Haufe, G.: Synthesis of Geminal Difluorides by Oxidative Desulfurization−Difluorination of Alkyl Aryl Thioethers with Halonium Electrophiles in the Presence of Fluorinating Reagents and Its Application for F-18-Radiolabeling. J Org Chem 75(18), 6086-6095, 2010.

Jahn, M., Radchenko, V., Filosofov, D.V., Hauser, H., Eisenhut, M., Rösch, F., Jennewein, M.: Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling. Radiochim Acta 98, 807-812, 2010.

Kratochwil, C., Giesel, F.L., López-Benítez, R., Schimpfky, N., Kunze, K., Eisenhut, M., Kauczor, H.U., Haberkorn, U.: Intraindividual comparison of selective arterial versus venous Ga-68-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 16(10), 2899-2905, 2010.

Kubas, H., Schäfer, M., Bauder-Wüst, U., Eder, M., Oltmanns, D., Haberkorn, U., Mier, W., Eisenhut, M.: Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding. Nucl Med Biol 37(8), 885-891, 2010.

Law, M.P., Schäfers, K., Kopka, K., Wagner, S., Schober, O., Schäfers, M.: Molecular Imaging of cardiac sympathetic innervation by [11C]mHED and PET – from man to mouse? J Nucl Med 51(8), 1269-1276, 2010.

Law, M.P., Wagner, S., Kopka, K., Renner, C., Pike, V.W., Schober, O., Schäfers, M.: Preclinical evaluation of an F-18-labelled β1-adrenoceptor selective radioligand based on ICI 89,406. Nucl Med Biol 37(4), 517-526, 2010.

Mühlhausen, U., Sihver, W., Ermert, J., Coenen, H.H.: Synthesis, radiofluorination and first evaluation of F-18-fluorophenylsulfonyl- and F-18-fluorophenylsulfinyl-piperidines as serotonin 5-HT2A receptor antagonists for PET. Nucl Med Biol 37(5), 605-614, 2010.

Nissen, F., Kraft, T.E., Ruppert, T., Eisenhut, M., Haberkorn, U., Mier, W.: Hot or not - the influence of elevated temperature and microwave irradiation on the solid phase synthesis of an affibody. Tetrahedron Lett 51, 6216-6219, 2010.

Sarko, D., Beijer, B., Boy, R.G., Nothelfer, E.M., Leotta, K., Eisenhut, M., Altmann, A., Haberkorn, U., Mier, W.: The Pharmacokinetics of Cell-Penetrating Peptides. Mol Pharm 7(6), 2224-2231, 2010.

Tsotsalas, M.*, Kopka, K.*, Luppi, G., Wagner, S., Law, M., Schäfers, M., DeCola, L.: Encapsulating 111In in nanocontainers for scintigraphic imaging: synthesis, characterization and in vivo biodistribution. ACS Nano 4(1), 342-348, 2010. *contributed equally

Wängler, C., Maschauer, S., Prante, O., Schäfer, M., Schirrmacher, R., Bartenstein, P., Eisenhut, M., Wängler, B.: Multimerization of cRGD Peptides by Click Chemistry: Synthetic Strategies, Chemical Limitations, and Influence on Biological Properties. ChemBioChem 11(15), 2168-2181, 2010.


Faust, A., Waschkau, B., Waldeck, J., Höltke, C., Breyholz, H.-J., Wagner, S., Kopka, K., Heindel, W., Schäfers, M., Bremer, C.: Synthesis and Evaluation of a Novel Hydroxamate Based Fluorescent Photoprobe for Imaging of Matrix Metalloproteinases. Bioconjugate Chem 20(5), 904-912, 2009.

Greguric, I., Taylor, S.R., Denoyer, D., Ballantyne, P., Berghofer, P., Roselt, P., Pham, T.Q., Mattner, F., Bourdier, T., Neels, O.C., Dorow, D.S., Loc'h, C., Hicks, R.J., Katsifis, A.: Discovery of F-18-N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. J Med Chem 52(17), 5299-5302, 2009.

Höltke, C., Law, M.P., Wagner, S., Kopka, K., Faust, A., Breyholz, H.J., Schober, O., Bremer, C., Riemann, B., Schäfers, M.: PET-compatible endothelin receptor radioligands: Synthesis and first in vitro and in vivo studies. Bioorg Med Chem 17(20), 7197-7108, 2009.

Höltke, C., Waldeck, J., Kopka, K., Heindel, W., Schober, O., Schäfers, M., Bremer, C.: Biodistribution of a nonpeptidic fluorescent Endothelin A receptor imaging probe. Mol Imaging 8(1), 27-34, 2009.

Kießling, F., Huppert, J., Zhang, C.F., Jayapaul, J., Zwick, S., Woenne, E.C., Mueller, M.M., Zentgraf, H., Eisenhut, M., Addadi, Y., Neeman, M., Semmler, W.: RGD-labeled USPIO Inhibits Adhesion and Endocytotic Activity of alphavbeta3-Integrin-expressing Glioma Cells and Only Accumulates in the Vascular Tumor Compartment. Radiology 253(2), 462-469, 2009.

Koopmans, K.P., Neels, O.N., Kema, I.P., Elsinga, P.H., Links, T.P., de Vries, E.G., Jager, P.L.: Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol 71(3), 199-213, 2009.

Mühlhausen, U., Ermert, J., Coenen, HH.: Synthesis, labelling and first evaluation of F-18-R91150 as a serotonin 5-HT2A antagonist for PET. J Label Compds Radiopharm 52, 13-23, 2009.

Mühlhausen, U., Ermert, J., Herth, M.M., Coenen, H.H.: Synthesis, radiofluorination and first evaluation of (±)-F-18-MDL 100907 as serotonin 5-HT2A receptor antagonist for PET. J Label Compds Radiopharm 52, 6-12, 2009.

Nothelfer, E.M., Zitzmann-Kolbe, S., Garcia-Boy, R., Krämer, S., Herold-Mende, C., Altmann, A., Eisenhut, M., Mier, W., Haberkorn, U.: Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer. J Nucl Med 50(3), 426-434, 2009.

Podichetty, A.K., Faust, A., Kopka, K., Wagner, S., Schäfers, M., Schober, O., Haufe, G.: Fluorinated Isatin Derivatives. Part 1: Synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)-sulfonyl]isatins as potent caspase-3 and -7 inhibitors. Bioorg Med Chem 17(7), 2680-2688, 2009.

Podichetty, A.K., Wagner, S., Schröer, S., Faust, A., Schäfers, M., Schober, O., Kopka, K., Haufe, G.: Fluorinated isatin derivatives. Part 2. New N-substituted 5-Pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis. J Med Chem 52(11), 3484-3495, 2009.

Podichetty, A.K., Wagner, S., Faust, A., Schäfers, M., Schober, O., Kopka, K., Haufe, G.: Fluorinated isatin derivatives. Part 3. New side-chain fluoro-functionalized pyrrolidinyl sulfonyl isatins as potent caspase-3 and -7 inhibitors. Future Med Chem 1(5), 969-989, 2009.

Wagner, S., Breyholz, H.J., Höltke, C., Faust, A., Schober, O., Schäfers, M., Kopka, K.: A new F-18-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies. Appl Radiat Isot 67(4), 606-610, 2009.

nach oben